<DOC>
	<DOCNO>NCT02121418</DOCNO>
	<brief_summary>This clinical trial study decitabine cytarabine treat old patient newly diagnose acute myeloid leukemia , myelodysplastic syndrome likely come back spread place body , myeloproliferative neoplasm . Drugs use chemotherapy , decitabine cytarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving decitabine cytarabine may work well standard therapy treat cancer bone marrow blood cell , acute myeloid leukemia , myelodysplastic syndrome , myeloproliferative neoplasm .</brief_summary>
	<brief_title>Decitabine Cytarabine Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia , High Risk Myelodysplastic Syndrome , Myeloproliferative Neoplasm</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Examine whether combination decitabine give 10 day ( day 1-10 ) , rather usual 5 day , plus `` standard dose cytarabine ( ara-C ) ( 100 mg/m^2 daily day 1-7 ) might improve 6-month survival probability historical 65 % 80 % patient age &gt; = 60 newly diagnose acute myeloid leukemia ( AML ) . II . Test whether combination might maintain complete response ( CR ) rate historic 45 % patient . III . Study factor lead physician escalate maintain ara-C dos patient `` intermediate response '' short CR first 2 cycle combination . IV . While maintain awareness confound covariates , examine effect dose escalation CR rate . OUTLINE : Patients receive decitabine intravenously ( IV ) daily day 1-10 cytarabine IV daily ( QD ) day 1-7 . Treatment repeat every 28-35 day 2 course absence disease progression unacceptable toxicity . After course 3 , patient achieve remission receive 1-2 course therapy dose . Patients remission significant side effect receive decitabine cytarabine decrease dos . Patients achieve remission receive treatment . After completion study treatment , patient follow 6 month periodically .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Newlydiagnosed AML World Health Organization ( WHO ) criterion ( &gt; = 20 % myeloid blast morphology either blood marrow ) Highrisk myelodysplastic syndrome ( MDS ) myeloproliferative neoplasm ( MPN ) include chronic myelomonocytic leukemia 2 ( CMML2 ) define 1019 % myeloid blast either blood marrow Patients may receive azacitidine , decitabine , lenalidomide `` cytotoxic therapy '' araC anthracyclines ; data suggest failure respond azacitidine reduce probability response 3+7 ; hence interest relatively homogeneous population , patient receive failed azacitidine decitabine eligible study , analyze separately patient receive drug Treatment related mortality ( TRM ) score &lt; 22.9 ; patient TRM score &gt; 13.1 , risk death within 28 day begin induction therapy average 41 % , preferentially place protocol 2642 Provision write informed consent Note , unlike pharmaceutical company sponsor protocol eligibility condition bilirubin , creatinine , absence malignancy within past 23 year ; TRM score incorporates creatinine thus high creatinine principle offset favorable value covariates TRM score ; bilirubin covariate TRM ; furthermore , dos use , dose adjustment decitabine araC indicate presence renal hepatic abnormality ; broad eligibility criterion may increase likelihood result generalizable ; inability reproduce result early phase AML study problem past</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>